1. Home
  2. IOVA vs CURB Comparison

IOVA vs CURB Comparison

Compare IOVA & CURB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • CURB
  • Stock Information
  • Founded
  • IOVA 2007
  • CURB 2024
  • Country
  • IOVA United States
  • CURB United States
  • Employees
  • IOVA N/A
  • CURB N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • CURB
  • Sector
  • IOVA Health Care
  • CURB
  • Exchange
  • IOVA Nasdaq
  • CURB NYSE
  • Market Cap
  • IOVA 771.4M
  • CURB 2.4B
  • IPO Year
  • IOVA N/A
  • CURB N/A
  • Fundamental
  • Price
  • IOVA $1.88
  • CURB $22.83
  • Analyst Decision
  • IOVA Buy
  • CURB Buy
  • Analyst Count
  • IOVA 10
  • CURB 7
  • Target Price
  • IOVA $12.22
  • CURB $26.29
  • AVG Volume (30 Days)
  • IOVA 10.4M
  • CURB 554.9K
  • Earning Date
  • IOVA 08-07-2025
  • CURB 08-07-2025
  • Dividend Yield
  • IOVA N/A
  • CURB 2.81%
  • EPS Growth
  • IOVA N/A
  • CURB N/A
  • EPS
  • IOVA N/A
  • CURB 0.11
  • Revenue
  • IOVA $212,679,000.00
  • CURB $131,537,000.00
  • Revenue This Year
  • IOVA $86.62
  • CURB $34.07
  • Revenue Next Year
  • IOVA $69.95
  • CURB $13.12
  • P/E Ratio
  • IOVA N/A
  • CURB $206.68
  • Revenue Growth
  • IOVA 11070.12
  • CURB 31.90
  • 52 Week Low
  • IOVA $1.64
  • CURB $18.80
  • 52 Week High
  • IOVA $12.51
  • CURB $25.69
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 47.47
  • CURB N/A
  • Support Level
  • IOVA $1.68
  • CURB N/A
  • Resistance Level
  • IOVA $2.02
  • CURB N/A
  • Average True Range (ATR)
  • IOVA 0.11
  • CURB 0.00
  • MACD
  • IOVA 0.03
  • CURB 0.00
  • Stochastic Oscillator
  • IOVA 61.42
  • CURB 0.00

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About CURB CURBLINE PPTYS CORP

Curbline Properties Corp is engaged in the business of owning, managing, leasing and acquiring a portfolio of convenience shopping centers. The primary source of the Company's income is generated from the rental of the Company's convenience shopping centers to tenants. Convenience shopping centers are generally positioned on the curbline of well-trafficked intersections and major vehicular corridors, offering excellent access and visibility, dedicated parking and often include drive-thru units, with approximately half of Curbline properties having at least one drive-thru unit.

Share on Social Networks: